Pet Cancer Therapeutics Market, by Therapy Type, Pet Type, Mode of Administration, Application, and Region - Global Trends, and Forecast, 2022 - 2028

Pet Cancer Therapeutics Market, by Therapy Type, Pet Type, Mode of Administration, Application, and Region - Global Trends, and Forecast, 2022 - 2028

The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.
Market Dynamics
The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2021, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.
Key features of the study:

This report provides in-depth analysis of pet cancer therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pet cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global pet cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

Global Pet Cancer Therapeutics Market, By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

Global Pet Cancer Therapeutics Market, By Pet Type:

Cat
Dog
Horse

Global Pet Cancer Therapeutics Market, By Mode of Administration:

Oral
Intravenous
Topical

Global Pet Cancer Therapeutics Market, By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

Global Pet Cancer Therapeutics Market, By Geography:

North America

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

U.S.
Canada

Latin America

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Europe

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

GCC
Israel
Rest of Middle East

Africa

By Therapy Type:

Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy

By Pet Type:

Cat
Dog
Horse

By Mode of Administration:

Oral
Intravenous
Topical

By Application:

Lymphoma
Mast Cell Cancer
Melanoma
Mammary and Squamous Cell Cancer
Others

By Country:

South Africa
Central Africa
North Africa

Company Profiles

Aratana Therapeutics, Inc.*

Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments

AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc.
VetDC, Inc.
Karyopharm Therapeutics, Inc.
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis

 “*” marked represents similar segmentation in other categories in the respective section.